Status: Recruiting
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.
Participants needed: 36
Trial details
Phase: Phase 2Age: 20+Biological sex: FemaleType: InterventionalSponsor: PhytoHealth CorporationUpdated: Jun 5, 2025Locations: 1
Eligibility criteria
Women aged ≥ 20 years [+11]
Known brain metastasis or primary CNS malignancy [+14]